jnj-64417184 + lansoprazole

JNJ-64417184 + lansoprazole is a combination of an investigational small molecule inhibitor, jnj-64417184, and the approved proton pump inhibitor, lansoprazole. JNJ-64417184 is a potential therapeutic for respiratory syncytial virus (RSV) infection; it acts by inhibiting the viral polymerase, thereby blocking viral RNA synthesis and production of new virions[2][3][5][6]. Lansoprazole is a well-established acid-reducing agent that inhibits the H+/K+ ATPase (proton pump) in gastric parietal cells, reducing gastric acidity. This combination has been tested in a clinical pharmacokinetic study to evaluate interaction effects (absorption, elimination, safety/tolerability) when both are administered together in healthy adults.

Other names

respiratory syncytial virus polymerase inhibitor + lansoprazole